FDA Trademark Policy Is Reducing "Coming Soon" Ads, Pharmacia Exec Says
Executive Summary
Pharmaceutical companies are cutting back on "coming soon" ads in light of the closer scrutiny trade names are receiving at FDA, Pharmacia Senior Director of Trademarks Cynthia Summerfield told the Food & Drug Law Institute annual meeting April 19 in Washington, D.C.
You may also be interested in...
FDA Drug Name Policy "Discourages" New Brand Names For Old Ingredients
FDA's Office of Postmarketing Drug Risk Assessment is "discouraging" applications that would create a new brand name for an existing active ingredient.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials